NO20042634L - 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser - Google Patents
3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaserInfo
- Publication number
- NO20042634L NO20042634L NO20042634A NO20042634A NO20042634L NO 20042634 L NO20042634 L NO 20042634L NO 20042634 A NO20042634 A NO 20042634A NO 20042634 A NO20042634 A NO 20042634A NO 20042634 L NO20042634 L NO 20042634L
- Authority
- NO
- Norway
- Prior art keywords
- cyanoquinolines
- egf
- inhibitors
- her2 kinases
- her2
- Prior art date
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical class C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33356801P | 2001-11-27 | 2001-11-27 | |
| PCT/US2002/037918 WO2003050090A1 (en) | 2001-11-27 | 2002-11-26 | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20042634L true NO20042634L (no) | 2004-06-23 |
Family
ID=23303345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042634A NO20042634L (no) | 2001-11-27 | 2004-06-23 | 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6821988B2 (de) |
| EP (1) | EP1448531B1 (de) |
| JP (1) | JP2005514384A (de) |
| KR (1) | KR20050044599A (de) |
| CN (1) | CN1659145A (de) |
| AR (1) | AR037438A1 (de) |
| AT (1) | ATE370123T1 (de) |
| AU (1) | AU2002359489B2 (de) |
| BR (1) | BR0214485A (de) |
| CA (1) | CA2467573A1 (de) |
| CO (1) | CO5580828A2 (de) |
| DE (1) | DE60221886D1 (de) |
| EC (1) | ECSP045122A (de) |
| HU (1) | HUP0402228A2 (de) |
| IL (1) | IL161921A0 (de) |
| MX (1) | MXPA04004969A (de) |
| NO (1) | NO20042634L (de) |
| NZ (1) | NZ533118A (de) |
| PL (1) | PL370137A1 (de) |
| RU (1) | RU2309150C2 (de) |
| TW (1) | TW200300348A (de) |
| UA (1) | UA77469C2 (de) |
| WO (1) | WO2003050090A1 (de) |
| ZA (1) | ZA200405025B (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1415987B1 (de) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
| ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
| AU2004266572A1 (en) * | 2003-08-01 | 2005-03-03 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| US7365203B2 (en) * | 2003-09-15 | 2008-04-29 | Wyeth | Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile |
| AU2003304497B2 (en) * | 2003-09-15 | 2010-06-24 | Wyeth Llc | Substituted quinolines as protein tyrosine kinase enzyme inhibitors |
| US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| US7781591B2 (en) | 2006-06-13 | 2010-08-24 | Wyeth Llc | Substituted 3-cyanopyridines as protein kinase inhibitors |
| WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| US7456176B2 (en) | 2004-04-08 | 2008-11-25 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| RU2007109073A (ru) | 2004-08-13 | 2008-09-20 | Дженентек, Инк. (Us) | Ингибиторы для атф-зависимого фермента на основе тиазола |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| TW200616612A (en) * | 2004-10-08 | 2006-06-01 | Wyeth Corp | Method for the teatment of polycystic kidney disease field of invention |
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| US7624279B2 (en) * | 2005-06-29 | 2009-11-24 | Lenovo Singapore Pte. Ltd. | System and method for secure O.S. boot from password-protected HDD |
| EP1925676A4 (de) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Testverfahren für die wirkung eines vaskularisierungsinhibitors |
| US7528143B2 (en) | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| TW200815407A (en) * | 2006-06-13 | 2008-04-01 | Wyeth Corp | Substituted 3-cyanopyridines as protein kinase inhibitors |
| KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| EP2119707B1 (de) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| ITMI20082336A1 (it) * | 2008-12-29 | 2010-06-30 | Univ Parma | Composti inibitori irreversibili di egfr con attivita' antiproliferativa |
| EA038195B1 (ru) | 2009-01-16 | 2021-07-22 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimen comprising neratinib for the treatment of cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| BR112012003592B8 (pt) | 2009-08-19 | 2021-05-25 | Eisai R&D Man Co Ltd | composição farmacêutica contendo derivado de quinolina |
| NZ599762A (en) | 2009-11-09 | 2014-07-25 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| ES2773693T3 (es) * | 2010-06-09 | 2020-07-14 | Tianjin Hemay Oncology Pharmaceutical Co Ltd | Derivados de cianoquinolina |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US9364479B2 (en) | 2010-08-26 | 2016-06-14 | Symphony Evolution, Inc. | Use of a receptor-type kinase modulator for treating polycystic kidney disease |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CN102675287A (zh) * | 2011-03-11 | 2012-09-19 | 江苏恒瑞医药股份有限公司 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
| EP2700403B1 (de) | 2011-04-18 | 2015-11-25 | Eisai R&D Management Co., Ltd. | Therapeutikum für tumor |
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| CN103304494B (zh) * | 2013-06-20 | 2015-05-27 | 河北大学 | 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途 |
| CA2957005C (en) | 2014-08-28 | 2021-10-12 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| WO2016210345A1 (en) | 2015-06-25 | 2016-12-29 | The California Institute For Biomedical Research | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| WO2017117474A1 (en) * | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
| WO2017148391A1 (zh) * | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| IL271973B (en) | 2017-07-28 | 2022-08-01 | Yuhan Corp | An improved process for the preparation of aminopyrimidine derivatives |
| CN110452232A (zh) * | 2019-09-17 | 2019-11-15 | 北京振东光明药物研究院有限公司 | 阿法替尼杂质化合物及其制备方法与应用 |
| CN111995618B (zh) * | 2020-09-02 | 2021-06-11 | 重庆医科大学 | 一种来那替尼杂质g的制备方法 |
| CN111943933B (zh) * | 2020-09-02 | 2021-05-28 | 重庆医科大学 | 一种来那替尼杂质d的制备方法 |
| EP4682143A1 (de) * | 2023-03-10 | 2026-01-21 | Convalife Pharmaceuticals Co., Ltd. | Pharmazeutische zusammensetzung mit egfr-hemmer sowie herstellungsverfahren dafür und verwendung davon |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997030035A1 (en) * | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| AU6159499A (en) * | 1998-09-29 | 2000-04-17 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| HUP0103520A3 (en) * | 1998-09-29 | 2003-01-28 | Wyeth Holdings Corp Madison | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them |
| GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| DK1242382T3 (da) * | 1999-12-29 | 2007-05-07 | Wyeth Corp | Tricycliske proteinkinaseinhibitorer |
| AU2002210714A1 (en) * | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
-
2002
- 2002-11-26 IL IL16192102A patent/IL161921A0/xx unknown
- 2002-11-26 WO PCT/US2002/037918 patent/WO2003050090A1/en not_active Ceased
- 2002-11-26 AT AT02794031T patent/ATE370123T1/de not_active IP Right Cessation
- 2002-11-26 BR BR0214485-9A patent/BR0214485A/pt not_active IP Right Cessation
- 2002-11-26 TW TW091134370A patent/TW200300348A/zh unknown
- 2002-11-26 CN CN028275381A patent/CN1659145A/zh active Pending
- 2002-11-26 EP EP02794031A patent/EP1448531B1/de not_active Expired - Lifetime
- 2002-11-26 HU HU0402228A patent/HUP0402228A2/hu unknown
- 2002-11-26 AR ARP020104543A patent/AR037438A1/es not_active Application Discontinuation
- 2002-11-26 MX MXPA04004969A patent/MXPA04004969A/es active IP Right Grant
- 2002-11-26 NZ NZ533118A patent/NZ533118A/en unknown
- 2002-11-26 RU RU2004119414/04A patent/RU2309150C2/ru not_active IP Right Cessation
- 2002-11-26 US US10/305,438 patent/US6821988B2/en not_active Expired - Fee Related
- 2002-11-26 PL PL02370137A patent/PL370137A1/xx not_active Application Discontinuation
- 2002-11-26 JP JP2003551115A patent/JP2005514384A/ja not_active Ceased
- 2002-11-26 CA CA002467573A patent/CA2467573A1/en not_active Abandoned
- 2002-11-26 KR KR1020047007951A patent/KR20050044599A/ko not_active Withdrawn
- 2002-11-26 AU AU2002359489A patent/AU2002359489B2/en not_active Ceased
- 2002-11-26 UA UA20040605019A patent/UA77469C2/uk unknown
- 2002-11-26 DE DE60221886T patent/DE60221886D1/de not_active Expired - Lifetime
-
2004
- 2004-05-25 CO CO04048181A patent/CO5580828A2/es not_active Application Discontinuation
- 2004-05-26 EC EC2004005122A patent/ECSP045122A/es unknown
- 2004-06-23 NO NO20042634A patent/NO20042634L/no not_active Application Discontinuation
- 2004-06-24 ZA ZA200405025A patent/ZA200405025B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003050090A1 (en) | 2003-06-19 |
| HUP0402228A2 (hu) | 2005-02-28 |
| RU2004119414A (ru) | 2006-02-27 |
| PL370137A1 (en) | 2005-05-16 |
| MXPA04004969A (es) | 2004-08-11 |
| NZ533118A (en) | 2006-07-28 |
| CA2467573A1 (en) | 2003-06-19 |
| CO5580828A2 (es) | 2005-11-30 |
| IL161921A0 (en) | 2005-11-20 |
| CN1659145A (zh) | 2005-08-24 |
| ZA200405025B (en) | 2006-12-27 |
| ECSP045122A (es) | 2004-07-23 |
| AR037438A1 (es) | 2004-11-10 |
| US6821988B2 (en) | 2004-11-23 |
| RU2309150C2 (ru) | 2007-10-27 |
| AU2002359489A1 (en) | 2003-06-23 |
| EP1448531A1 (de) | 2004-08-25 |
| ATE370123T1 (de) | 2007-09-15 |
| AU2002359489B2 (en) | 2008-10-30 |
| EP1448531B1 (de) | 2007-08-15 |
| BR0214485A (pt) | 2004-09-14 |
| DE60221886D1 (de) | 2007-09-27 |
| UA77469C2 (en) | 2006-12-15 |
| KR20050044599A (ko) | 2005-05-12 |
| JP2005514384A (ja) | 2005-05-19 |
| US20030149056A1 (en) | 2003-08-07 |
| TW200300348A (en) | 2003-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161921A0 (en) | 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases | |
| NO20050636L (no) | Inhibitorer av tyrosinkinaser | |
| NO20052888D0 (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
| NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
| NO20041582L (no) | Antistoffinhibitorer av GDF-8 og anvendelse derav | |
| IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
| NO20052595D0 (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
| ATE370938T1 (de) | Pro-pharmakon von cox-2-inhibitoren | |
| NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
| NO20026010L (no) | Substituerte quinazolinderivater og deres anvendelse som inhibitorer | |
| IS6968A (is) | Nýir týrósínkínasa tálmar | |
| NO20033387D0 (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
| DK1370554T3 (da) | 3-(4-Amidopyrrol-2-ylmethyliden)-2-indolinon-derivater som proteinkinaseinhibitorer | |
| NO20045220L (no) | Heterocykliske inhibitorer for kinaser | |
| EP1534268A4 (de) | Tyrosin-kinase-hemmer | |
| NO20053356L (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
| DK1480962T3 (da) | 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer | |
| NO20053242D0 (no) | 4-substituerte benzimidazoler og deres anvendelse som inhibitorer av gastrisk sekresjon. | |
| AU2002357882A8 (en) | Small-molecule inhibitors of interleukin-2 | |
| NO20042719L (no) | Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer | |
| NO20042244L (no) | Fenylsubstituerte triazoler og deres anvendelse som selektive inhibitorer av AKL5-kinease | |
| DE60319430D1 (de) | R- und fgfr-inhibitoren | |
| NO20033854L (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
| EP1651599A4 (de) | Tyrosin-kinase-hemmer | |
| NO20035328D0 (no) | Nye forbindelser og preparater som katepsinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |